Development of 18F-poly(2-oxazoline)-duramycin and 18Fpoly( 2-oxazoline)-RGD as radiotracers for in vivo imaging of tumor environment. 01/01/2014 - 31/12/2017


The main objective of this project is to improve the tumor targeting capability and pharmacokinetics of duramycin and RGD radiotracers using conjugation to POX for in vivo therapy evaluation in hypoxic and irradiated non small cell lung cancer. The use of a radiotracer with a better pharmacokinetic profile will result in better tumor/background ratio and faster differentiation between effective versus non-effective therapy thus in more efficient and cost-reducing personalized medicine.


Research team(s)

    Project type(s)

    • Research Project